Testing modified immune cells for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer).
- You must be able to do most daily activities (like walking, light chores) without help.
- If you could become pregnant, you must agree to use two forms of effective birth control during the study.
- You must be willing to sign a consent form and share your health information with the study team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
This trial tests an experimental cell therapy called MT-601 for pancreatic cancer that is advanced. The treatment uses your own immune cells to fight the cancer, and the goal is to see if it is safe and helps people whose cancer is stable or shrinking on chemotherapy.
This study tests a new type of immune therapy for pancreatic cancer. It uses your own immune cells, which are modified in the lab to find and attack cancer cells that have a specific protein called CD318.
This trial tests a new treatment using specially engineered immune cells (CAR macrophages) that are designed to find and attack a protein called c-MET on pancreatic cancer cells. It may help people whose cancer has not responded to previous treatments or who could not tolerate them.
This trial tests an experimental cell therapy using immune cells called iNKT cells, which are designed to attack pancreatic cancer. It may be an option for people who have already tried standard treatments and are looking for something new.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.